
Please add the following claims.

- 9. (New) The method of claim 4, wherein the sample is a fluid sample.
- 10. (New) The method of claim 9, wherein the fluid sample is blood.
- 11. (New) The method of claim 9, wherein the fluid sample is urine.
- 12. (New) The method of claim 4, wherein the subject is diabetic.
- 13. (New) The method of claim 4, wherein the subject is free of symptoms calling for a therapy with a sugar-regulating therapy.
- 14. (New) The method of claim 4, wherein the subject is undergoing therapy for regulating blood sugar levels.
- 15. (New) The method of claim 14, wherein the therapy is a non-drug therapy.
- 16. (New) The method of claim 14, wherein the therapy is a drug therapy.
- 17. (New) The method of claim 16, wherein the drug therapy is an oral blood sugar regulating agent therapy.
- 18. (New) The method of claim 16, wherein the drug therapy is an injectable drug therapy.
- 19. (New) The method of claim 16, wherein the drug therapy is insulin therapy or an insulin analog therapy.

Art Unit: 1644

- 20. (New) The method of claim 4, wherein the subject is at increased risk of becoming diabetic.
- 21. (New) The method of claim 4, wherein the control level is the level in apparently healthy normal individuals.
- 22. (New) The method of claim 4, wherein the control level is a predetermined value.
- 23. (New) The method of claim 4, wherein the control level is a level determined for the subject from a sample obtained from the subject at a time separated from the first sample.
- 24. (New) The method of claim 23, wherein the time is at least one day.
- 25. (New) The method of claim 4, wherein the subject has received treatment for regulating blood sugar levels.
- 26. (New) The method of claim 4, wherein the subject has not received treatment for regulating blood sugar levels.



- 28. (New) The method of claim 4, wherein the level is obtained using an immunoassay.
- 29. (New) The method of claim 4, wherein the level is measured as a percentage of the total CD59 in the sample.
- 30. (New) The method of claim 4, wherein the level is the level of K41-glycated CD59 relative to the level of K41-nonglycated CD59 in the sample.

625284.1

Art Unit: 1644

31. (New) The method of claim 4, wherein the level is obtained using an agent that binds specifically to K41-glycated CD59.

32. (New) The method of claim 31, wherein the agent is detectably labeled.

- 33. (New) The method of claim 31, wherein the agent is an antibody or antigen-binding fragment thereof.
- 34. (New) The method of claim 33, wherein the antibody is a monoclonal antibody.
- 35. (New) The method of claim 33 wherein the antibody is a polyclonal antibody.
- 36. (New) The method of claim 4 wherein the level is obtained using two agents, a first agent that binds both glycated and nonglycated CD59 and a second agent that binds only one of a glycated K41 and a nonglycated K41.
- 37. (New) The method of claim 36, wherein one or more of the first and second agents is detectably labeled.
- 38. (New) The method of claim 36, wherein one or more of the first and second agents is an antibody or antigen-binding fragment thereof.
- 39. (New) The method of claim 38, wherein one or more of the first and second antibodies is a monoclonal antibody.
- 40. (New) The method of claim 38, wherein one or more of the first and second antibodies is a polyclonal antibody.

625284.1